Ot­su­ka scores PhI­II win for an­oth­er As­tex drug; GSK ex­pands Nu­cala use in asth­ma

→ Ot­su­ka has some good news to re­port on the oth­er drug that it ob­tained in the $886 mil­lion ac­qui­si­tion of As­tex Phar­ma­ceu­ti­cals. ASTX727 com­bines the chemother­a­py decitabine with cedazuri­dine, an oral in­hibitor of cy­ti­dine deam­i­nase. A Phase III study eval­u­at­ing the com­bo and in­ter­me­di­ate to high-risk myelodys­plas­tic syn­drome and chron­ic myelomono­cyt­ic leukemia met its pri­ma­ry end­point, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER